



Antibodies

1P-614-C100

## Monoclonal Antibody to CD25 (mouse) Phycoerythrin (PE) conjugated (0.1 mg)

<b>Clone:</b>	PC61.5
<b>Isotype:</b>	Rat IgG1
<b>Specificity:</b>	The rat monoclonal antibody PC61.5 (PC61.5.3) recognizes CD25 (Interleukin-2 receptor alpha chain), a 55 kDa type I transmembrane glycoprotein expressed on activated B and T lymphocytes, activated monocytes/macrophages and on CD4 <sup>+</sup> T lymphocytes (T regulatory cells); it is lost on resting B and T lymphocytes.
<b>Regulatory Status:</b>	RUO
<b>Immunogen:</b>	B6.1 CTL cell line
<b>Species Reactivity:</b>	Mouse
<b>Preparation:</b>	The purified antibody is conjugated with R-Phycoerythrin (PE) under optimum conditions. The conjugate is purified by size-exclusion chromatography.
<b>Concentration:</b>	0.5 mg/ml
<b>Storage Buffer:</b>	Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4
<b>Storage / Stability:</b>	Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.
<b>Usage:</b>	The reagent is designed for Flow Cytometry analysis. Suggested working dilution is 2 µg/ml. Indicated dilution is recommended starting point for use of this product. Working concentrations should be determined by the investigator.
<b>Expiration:</b>	See vial label
<b>Lot Number:</b>	See vial label
<b>Background:</b>	CD25 (IL2Ralpha, Tac) is a ligand-binding alpha subunit of interleukin 2 receptor (IL2R). Together with beta and gamma subunit CD25 constitutes the high affinity IL2R, whereas CD25 alone serves as the low affinity IL2R. CD25 expression rapidly increases upon T cell activation. The 55 kDa CD25 molecule is enzymatically cleaved and shed from the cell surface as a soluble 45 kDa s-Tac, whose concentration in serum can be used as a marker of T cell activation. Expression of CD25 indicates the neoplastic phenotype of mast cells. CD25+ CD4+ FoxP3+ regulatory cells (Treg cells) play a crucial role in the control of organ-specific autoimmune diseases.

**For laboratory research only, not for drug, diagnostic or other use.**

**Antibodies****References:**

- \*Jones CM, Cose SC, Coles RM, Winterhalter AC, Brooks AG, Heath WR, Carbone FR: Herpes simplex virus type 1-specific cytotoxic T-lymphocyte arming occurs within lymph nodes draining the site of cutaneous infection. *J Virol.* 2000 Mar;74(5):2414-9.
- \*Kotner J, Tarleton R: Endogenous CD4(+) CD25(+) regulatory T cells have a limited role in the control of *Trypanosoma cruzi* infection in mice. *Infect Immun.* 2007 Feb;75(2):861-9.
- \*Van VQ, Darwiche J, Raymond M, Lesage S, Bouguermouh S, Rubio M, Sarfati M: Cutting edge: CD47 controls the in vivo proliferation and homeostasis of peripheral CD4+ CD25+ Foxp3+ regulatory T cells that express CD103. *J Immunol.* 2008 Oct 15;181(8):5204-8.
- \*Kish DD, Gorbachev AV, Fairchild RL: CD8+ T cells produce IL-2, which is required for CD(4+)CD25+ T cell regulation of effector CD8+ T cell development for contact hypersensitivity responses. *J Leukoc Biol.* 2005 Sep;78(3):725-35.
- \*Aiba Y, Hirayama F, Ogawa M: Clonal proliferation and cytokine requirement of murine progenitors for natural killer cells. *Blood.* 1997 Jun 1;89(11):4005-12.
- \*Yu CT, Feng MH, Shih HM, Lai MZ: Increased p300 expression inhibits glucocorticoid receptor-T-cell receptor antagonism but does not affect thymocyte positive selection. *Mol Cell Biol.* 2002 Jul;22(13):4556-66.
- \*Wei HX, Chuang YH, Li B, Wei H, Sun R, Moritoki Y, Gershwin ME, Lian ZX, Tian Z: CD4+ CD25+ Foxp3+ regulatory T cells protect against T cell-mediated fulminant hepatitis in a TGF-beta-dependent manner in mice. *J Immunol.* 2008 Nov 15;181(10):7221-9.
- \*Tenorio EP, Olguín JE, Fernández J, Vieyra P, Saavedra R: Reduction of Foxp3+ cells by depletion with the PC61 mAb induces mortality in resistant BALB/c mice infected with *Toxoplasma gondii*. *J Biomed Biotechnol.* 2010;2010:786078.
- \*And many other.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at [www.exbio.cz](http://www.exbio.cz).

**For laboratory research only, not for drug, diagnostic or other use.**

EXBIO Praha | Nad Safinou II 341 | 252 50 Vestec u Prahy | Czech Republic  
Tel: +420 261 090 666 | Fax: +420 261 090 660 | [orders@exbio.cz](mailto:orders@exbio.cz) | [www.exbio.cz](http://www.exbio.cz)